Apollo Hospitals Enterprise posted a 34% surge in Q1 FY27 net profit to ₹581 crore, supported by a 20.6% revenue rise. While hospital occupancy hit 70%, the stock fell nearly 2% on Wednesday as investors likely engaged in profit-booking. The company also announced a 5,800-bed expansion plan and a new auditor appointment.
Apollo Hospitals Enterprise reported a strong start to fiscal year 2027, with consolidated net profit rising 34.2% to ₹581 crore for the first quarter ended June 30, 2026. The company’s revenue from operations grew 20.6% to ₹7,044 crore during the same period. This performance was driven by a rise in patient volumes and a 70% occupancy rate across its hospital network, compared to 65% in the same quarter last year.
Operational Growth and Financials
The healthcare services division remained the primary growth driver, contributing ₹3,567 crore in revenue, marking a 22% increase year-on-year. Operating margins also improved, with EBITDA rising 28.2% to ₹1,092 crore, leading to an EBITDA margin of 15.5%. Apollo HealthCo, which includes the pharmacy and digital businesses, reported a 20% revenue growth to ₹2,977 crore. Its EBITDA performance was particularly notable, nearly doubling to ₹171 crore, reflecting increased efficiency in its offline pharmacy distribution and digital platforms.
Despite the positive quarterly results, the company’s share price declined by approximately 1.7% to 2% during Wednesday's trading session. This market reaction often occurs when a stock is trading at a high valuation, and investors choose to sell after a positive earnings announcement to lock in gains. The stock's performance reflects a broader sentiment where investors weigh strong operational growth against the premium pricing commanded by major hospital chains.
Expansion and Governance Updates
Apollo Hospitals has set an aggressive roadmap for the next five years, with plans to add over 5,800 beds. This capacity expansion includes new facilities in locations such as Indore, Dwarka, and Ranchi. These investments are part of the company's broader strategy to enhance its national footprint, though investors will need to monitor how this capital spending impacts debt levels and cash flow in the coming quarters. In a separate development, the company’s board approved the appointment of Price Waterhouse Chartered Accountants LLP as the new statutory auditor for a five-year term starting from fiscal year 2027.
Risks to Monitor
While the company has shown consistent growth, several factors could influence its future performance. The healthcare sector often faces regulatory scrutiny regarding pricing and operations, which can impact profitability. Additionally, the company relies partly on medical tourism, making it sensitive to geopolitical tensions that might disrupt patient travel from West Asia. Furthermore, high competition in the hospital sector and the potential for higher interest rates affecting the cost of funding large expansions are factors that market participants monitor closely. The success of the planned restructuring, including the combination of Apollo Health and Lifestyle with Cloudnine, will also be a key update for shareholders.